Journal of International Oncology››2013,Vol. 40››Issue (11): 867-870.doi:10.3760/cma.j.issn.1673-422X.2013.11.020
Previous ArticlesNext Articles
Xia-Ting, ZHANG Le-Hong, CAO Teng-Fei, et al
Online:
2013-11-08Published:
2013-10-15Contact:
XIA Ting, E-mail: 31433541@qq.com E-mail:31433541@qq.comXia-Ting, ZHANG Le-Hong, CAO Teng-Fei, et al. Expression and prognostic significance of TK1 and Ki67 in breast cancer[J]. Journal of International Oncology, 2013, 40(11): 867-870.
[1] Johnson LF, Rao LG, Muench AJ. Regulation of thymidine kinase enzyme level in serumstimulated mouse 3T6 fibroblasts. Exp Cell Res, 1982,138(1):79-85. [2] Wu BJ, Li WP, Qian C, et al. Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma. Tumour Biol, 2013,34(2):643-648. [3] Mao Y, Wu J, Skog S, et al. Expression of cell proliferating genes in patients with nonsmall cell lung cancer by immunohistochemistry and cDNA profiling. Oncol Rep, 2005, 13(5):837-846. [4] Broet P, Romain S, Daver A, et al. Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. J Clin Oncol, 2001,19(11):2778-2787. [5] 李树玲. 乳腺癌防治研究回顾与展望. 国外医学肿瘤学分册, 2000, 27(1): 14-17. [6] He Q, Fornander T, Johansson H, et al. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res, 2006,26(6C):4753-4759. [7] Zhang J, Jia Q, Zou S, et al. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep, 2006,15(2):455-461. [8] Agarwal HK, McElroy CA, Sjuvarsson E, et al. Synthesis of N3-substituted carboranyl thymidine bioconjugates and their evaluation as substrates of recombinant human thymidine kinase 1. Eur J Med Chem, 2013, 60:456-468. [9] Huang ZH, Tian XS, Li R, et al. Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer. Exp Ther Med, 2012,3(2):331-335. [10] Liu Y, Ling Y, Qi Q, et al. Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer. Exp Ther Med, 2011, 2(6):1177-1181. [11] Huang ZH, Tian XS, Li R, et al. Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer. Exp Ther Med, 2012,3(2):331-335. [12] Kang NH, Hwang KA, Yi BR, et al. Human amniotic fluid-derived stem cells expressing cytosine deaminase and thymidine kinase inhibits the growth of breast cancer cells in cellular and xenograft mouse models. Cancer Gene Ther, 2012,19(6): 412-419. [13] 陈飞宇, 唐利立, 黄隽. S-TK1在乳腺癌患者新辅助化疗前后检测的意义. 中国肿瘤临床, 2009,36(13):732735. [14] Mohammed ZM, McMillan DC, Elsberger B, et al. Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer, 2012, 106(2):383- 388. [15] Veronese SM, Gambacorta M, Gottardi O, et al. Proliferation index as a prognostic marker in breast cancer. Cancer, 1993, 71(12): 3926-3931. |
[1] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[2] | Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234. |
[3] | Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238. |
[4] | Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82. |
[5] | Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer: present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58. |
[6] | Wang Jing, Xu Wenting.Value of NLR, CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526. |
[7] | Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531. |
[8] | Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456. |
[9] | Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462. |
[10] | Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356. |
[11] | Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367. |
[12] | Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240. |
[13] | Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149. |
[14] | Li Lixi, Zhang Di, Luo Yang, Ma Fei.Clinical application of PARP inhibitors in breast cancer[J]. Journal of International Oncology, 2023, 50(2): 91-96. |
[15] | Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng.Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors[J]. Journal of International Oncology, 2023, 50(11): 650-654. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||